Safety and Toxicity Management of HER2-Directed ADCs in Clinical Practice

This segment addresses the safety profile and toxicity management of HER2-targeted ADCs, a critical consideration for oncologists integrating these therapies into routine practice. Drs. Santos and Lopes emphasize that while ADCs offer significant efficacy benefits, they are associated with unique adverse events that require proactive monitoring and management.

A central focus is the risk of interstitial lung disease (ILD)/pneumonitis, a potentially serious toxicity that necessitates early recognition and prompt intervention. The speakers discuss clinical vigilance, including monitoring respiratory symptoms and the importance of imaging when clinically indicated.

Other commonly observed adverse events, such as gastrointestinal toxicity (nausea, vomiting), fatigue, and hematologic effects, are also reviewed. The faculty highlight supportive care strategies and dose modification approaches to maintain treatment adherence while minimizing toxicity.

The discussion underscores the importance of patient education, multidisciplinary coordination, and adherence to prescribing guidelines. These considerations are essential for optimizing outcomes and reducing treatment interruptions.

Effective toxicity management, including early detection and intervention, is integral to safely delivering HER2-targeted therapies and maximizing the therapeutic index of these agents.